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Abstract
Background: The aim of this study was to assess the efficacy and safety of a combination regimen of capecitabine
plus cisplatin (CC) or capecitabine plus paclitaxel (CP) as a first-line treatment in patients with metastatic
esophageal squamous cell carcinoma.
Methods: Patients with recurrent or metastatic esophageal squamous cell carcinoma were enrolled in this
open-label, phase II, randomized trial. Patients were assigned to either the CC arm (days [D]1–14 capecitabine
1000 mg/m2 twice daily + D1 cisplatin 75 mg/m2, every 3 weeks) or the CP arm (D1–14 capecitabine 1000 mg/m2
twice daily + D1, 8 paclitaxel 80 mg/m2, every 3 weeks). The primary endpoint of the study was response rate and
secondary endpoints were progression-free survival (PFS), overall survival (OS), toxicity and quality of life.
Results: A total of 94 patients were entered into this study between October 2008 and October 2012, 46 patients
in the CC arm and 48 in the CP arm. Patients in both arms received a median of six cycles of treatment (range,
1–14) and the response rates were 57 and 58 % in the cisplatin and paclitaxel arm, respectively. With a median
follow-up of 23 months, the median PFS was 5.1 months (95 % CI 4.0–6.2 months) in the cisplatin arm and
6.7 months (95 % CI 4.9–8.5 months) in the paclitaxel arm, whereas the median OS was 10.5 months (95 %
CI 9.2–11.9 months) in the cisplatin arm and 13.2 months (95 % CI 9.4–17.0 months) in the paclitaxel arm. Patients
in the cisplatin arm were more likely to experience neutropenia and thrombocytopenia, whereas patients in the
paclitaxel arm had a higher frequency of neuropathy and alopecia. Quality of life was similar between treatment arms.
Conclusions: Both CC and CP regimens were effective and well tolerated as a first-line treatment in patients with
metastatic esophageal squamous cell carcinoma.
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Background
Esophageal cancer is the eighth most common cancer
worldwide [1]. It is estimated that 2199 new cases and
1352 deaths from esophageal cancer occur annually in
Korea [2]. Although there is variation in the predomin-
ant histological type among regions, the majority of
esophageal cancers represent squamous cell carcinoma
arising from the upper-and middle-third of the esopha-
gus. A large majority of patients present with advanced
disease that is beyond the scope of cure, and even after
surgical resection with curative intent more than 50 %
of patients will develop recurrence and/or distant me-
tastases [3].
Despite the lack of evidence for a survival benefit asso-
ciated with cytotoxic chemotherapy, administration of
fluoropyrimidine with or without cisplatin remains a
common treatment strategy for patients with metastatic
esophageal cancer. Similar to the results of clinical trials
performed in patients with adenocarcinoma arising from
the esophagus or stomach [4], a combination chemo-
therapy regimen of 5-fluorouracil and cisplatin was
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associated with response rates of up to 45 % in patients
with squamous cell esophageal cancer [5, 6]. There have
been efforts to substitute infusional 5-fluorouracil with
oral fluoropyrimidines for improved tolerability and pa-
tient convenience. Our own phase II study reported the
efficacy and tolerability of capecitabine plus cisplatin
(CC) in chemotherapy-naïve patients with metastatic
esophageal squamous cell carcinoma; the response rate
was 58 % and the median overall survival (OS) was
11.2 months [7].
Among many chemotherapeutic agents, taxanes (pacli-
taxel or docetaxel) have been investigated as single
agents or as combination therapy in this setting. When
combined with cisplatin, paclitaxel is associated with a
response rate of 40–50 % [8, 9]. Paclitaxel has also been
suggested as a partner for capecitabine-based chemother-
apy because taxanes upregulate the activity of thymidine
phosphorylase (TP) [10], which is an essential enzyme for
the activation of capecitabine. In addition to the possible
synergistic effect of a capecitabine and paclitaxel (CP)
combination, these agents have non-overlapping toxicities
and therefore can be combined with reasonable tolerabil-
ity. Combination chemotherapy with taxane plus capecita-
bine has been tested in a number of clinical trials and
showed favorable efficacy and safety [11, 12]. Previous
studies that explored different combination regimens in-
volving capecitabine prompted us to design this random-
ized phase II trial in order to evaluate the efficacy and
safety of CC and CP regimens in patients with metastatic
esophageal squamous cell carcinoma who had not been
previously treated.
Patients and methods
This was an open-label, single-center, randomized, paral-
lel phase II study (ClinicalTrials.gov NCT00816634).
The protocol was reviewed and approved by the insti-
tutional review board at Samsung Medical Center
((#200807059, Seoul, Korea) and the trial was con-
ducted in accordance with the Declaration of Helsinki.
Patients with recurrent or metastatic squamous cell car-
cinoma of the esophagus who had not previously been
treated palliative chemotherapy for metastatic disease
were eligible. Patients were required to have at least one
measurable metastatic lesion as defined by the Response
Criteria in Solid Tumors (RECIST) v1.0, an Eastern Co-
operative Oncology Group (ECOG) performance status
of 0–2, a life expectancy of at least 3 months, and ad-
equate hematologic (neutrophil count ≥ 1500/mm3,
platelet count ≥ 100,000/mm3, hemoglobin ≥ 9.0 g/dl),
renal (serum creatinine ≤ 1.5 mg/dl or creatinine clear-
ance ≥ 50 ml/min) and liver function (bilirubin ≤ 1.5 mg/
dl, AST/ALT ≤ 3 times the upper normal limit). Patients
with no prior chemotherapy or only adjuvant chemother-
apy that had been completed more than 6 months before
registration, and no radiotherapy within 4 weeks before
study registration were eligible. Patients who had other
types of esophageal cancer tumors, central nervous system
metastasis, severe comorbid illness, or active infection,
and women who were pregnant or lactating, were ex-
cluded from the study. The nature of the study was fully
discussed with the patients before the initiation of treat-
ment, including an explanation of the risks and possible
discomfort, as well as the potential benefits, and written
informed consent was obtained.
Eligible patients were stratified by their ECOG per-
formance status (0–1 vs. 2), and randomly assigned to
receive CC (capecitabine 1000 mg/m2 orally twice a day
on days 1–14 plus 75 mg/m2 of cisplatin intravenously
on day 1) or CP (capecitabine as for CC plus 80 mg/m2
of paclitaxel intravenously on days 1 and 8). An identical
dose regimen of capecitabine was used for both treat-
ment arms. Study treatment was repeated every 3 weeks
until documented disease progression, unacceptable tox-
icity, or patient refusal. Supportive care, including ad-
equate pre- and post-hydration for patients in the CC
arm and corticosteroids for patients in the CP arm, was
provided according to guidelines. The use of hematopoietic
growth factors was not allowed during treatment, except
for patients with febrile neutropenia or grade 4 myelosup-
pression at the investigators’ discretion. Each cycle of
chemotherapy was given if the patient’s blood counts had
returned to normal and non-hematologic toxicities had re-
solved. All patients received chemotherapy as outpatients.
After combination chemotherapy failed, second-line
chemotherapy was recommended to all patients if their
performance status was preserved.
The dosage of subsequent cycles was adjusted accord-
ing to the toxic effects that developed during the preced-
ing cycle. Baseline evaluation included a complete
medical history and physical examination, blood counts,
serum chemistry, chest x-ray, and chest computed tom-
ography (CT) scan. Follow-up history, physical examin-
ation and toxicity assessment were performed before
each 3-week cycle of treatment. Toxicity grading was
based on the National Cancer Institute criteria (NCI-
CTCAE version 3). The first evaluation with imaging
was performed 6 weeks after the start of study treat-
ment. Response was evaluated according to the RECIST
criteria and was assessed by chest CT or by the same
tests that were initially used to stage the tumor. In case
of complete radiologic response, endoscopic evaluation
of the primary tumor, if present, was mandatory. Progres-
sion in non-measurable lesions that led to deterioration of
patient status was classified as progressive disease regard-
less of the status of the measurable lesions. We also
assessed quality of life (QOL) using the EORTC-QLQ-
OES18, which contains four scales that address dysphagia,
eating difficulties, reflux, and esophageal pain, and six
Lee et al. BMC Cancer  (2015) 15:693 Page 2 of 7
single items for problems with coughing, dry mouth, taste,
choking when swallowing, speech, and swallowing saliva.
These self-administered questionnaires were completed
by patients at baseline, every two cycles, and at the end of
treatment. QOL scores were descriptively recorded as
baseline values and changes from baseline. As a general
criterion for clinically significant improvement or deterior-
ation, we defined a difference of ten or greater from base-
line mean score as a clinically significant change.
The primary objective of this study was to assess the
response rate in both treatment arms. Secondary objec-
tives included assessment of PFS, OS, toxicity and QOL.
This randomized phase II trial was statistically treated as
two simultaneous phase II studies and the Simon’s two-
stage optimal design was applied separately for each
treatment arm [13]. A sample size of 94 patients was re-
quired to accept the hypothesis that the true response
rate in each arm was greater than 40 % with 80 % power,
and to reject the hypothesis that the response rate was
less than 20 % with 5 % significance. In the first stage, if
there were fewer than four responses out of the initial
13 patients for each group, early termination of the
study was required. PFS and OS were estimated accord-
ing to the Kaplan-Meier method, and the changes in
QOL scores were calculated with a paired t-test. Since
the study was designed to assess chemotherapy out-
comes for two regimens simultaneously, exploratory
analyses of efficacy were carried out using the Cox regres-
sion model. All data were analyzed using R for Windows
software (version 2.11.1, http://www.r-project.org).
Results
Between October 2008 and October 2012, a total of 94
patients with esophageal squamous cell carcinoma were
registered for the study. After randomization, 46 patients
were allocated to the CC arm and 48 patients to the CP
arm (Fig. 1). The median age was 63 years (range 34–82
years) and the majority of patients were male (98 %) and
smokers (92 %). All patients had histologically proven
squamous cell carcinoma of the esophagus. Fifty-nine
patients had primary advanced disease and the remaining
35 had recurrent disease after prior surgery or definitive
chemoradiation. The most common site of metastasis was
supraclavicular or cervical lymph node (54 %), followed by
abdominal lymph node (45 %), lung (32 %), bone (18 %),
and liver (13 %). Baseline characteristics were available for
all patients and are listed in Table 1.
Treatment and adverse events
A total of 230 cycles of CC (median 6, range 1–12) and
278 cycles of CP (median 6, range 1–14) were delivered.
Among the 94 patients who started study treatment, the
main reasons for discontinuing treatment in the CC and
CP arms included progressive disease (30 % versus
33 %), toxicity (9 % versus 13 %), and patient refusal
(20 % versus 10 %). For patients treated with CC, the
median dose intensities of capecitabine (573 mg/m2/
week) and cisplatin (22 mg/m2/week) corresponded to
86 and 90 % of the scheduled doses. In the CP arm,
the median dose intensities of capecitabine and pacli-
taxel were 596 mg/m2/week and 48 mg/m2/week, re-
spectively (90 % of the scheduled doses). The median
duration of therapy was 4.5 months and 5.8 months
in the CC and CP arms, respectively (P = 0.064).
There was no significant difference in the occurrence
of overall grade 3 or 4 adverse events between the two
arms. The toxicity profiles are presented in Table 2. The
most common grade 3 or 4 adverse event was neutro-
penia, which occurred in 16 patients (40 %) in the CC
arm and 18 patients (38 %) in the CP arm. All grades of
neutropenia and thrombocytopenia were more fre-
quently observed in the CC arm, whereas peripheral
neuropathy, myalgia, and alopecia were more common
in the CP arm. Interstitial pneumonitis occurred in two
patients in the CP arm. This event, which resolved after
weeks of corticosteroid therapy, was possibly related to
study chemotherapy. Three patients died of causes for
which a relationship to the study treatment could not be
completely ruled out. One death as a result of tumor
bleeding occurred in the middle of the first CC cycle.
Another patient died of neutropenic sepsis after receiv-
ing a fifth CP cycle. The third patient, who was known
to have multiple lung and liver metastases, died of re-
spiratory failure after 10 months of clinical response to
CP. Since the tumor extent remained unchanged, the
possibility of drug-related pneumonitis was not com-
pletely excluded.
Fig. 1 Flow diagram of all registered patients
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Efficacy
Of the 94 patients, 11 could not be evaluated for clinical
response because of early discontinuation of therapy. In
an intent-to-treat principle, these patients were consid-
ered to have progressive disease.
The response rate was 57 and 58 % in the CC and CP
arms, respectively. Additionally, 10 (22 %) CC and 12
(25 %) CP patients had stable disease (Table 3). There-
fore, disease control (response plus disease stabilization)
was achieved in 78 and 83 % of patients treated with CC
and CP, respectively. Two CP patients exhibited
complete response to chemotherapy and discontinued
study treatment for resection with curative intent. The
median duration of response in the 54 responders was
6 months (range 1–38 months): 4 months in the CC
arm (range 1–31 months) and 7 months in the CP arm
(range 1–38 months). Although not specified in the
protocol, second-line chemotherapy was offered to 49
and 48 % of patients in the CC and CP arms, respect-
ively, after failure.
With a median follow-up duration of 23 months, the
median PFS was 5.1 months (95 % confidence interval
[CI] 4.0–6.2 months) in the CC arm and 6.7 months
(95 % CI 4.9–8.5 months) in the CP arm (Fig. 2). The
median OS was 10.5 months (95 % CI 9.2–11.9 months)
in the CC arm and 13.2 months (95 % CI 9.4–
17.0 months) in the CP arm (Fig. 3). These differences
were not statistically significant (log-rank P = 0.260 for
PFS and P = 0.217 for OS). Analysis with the Cox pro-
portional hazards model suggested that symptomatic
disease at baseline (P = 0.012) and multiple sites of me-
tastases (P = 0.028) affected the risk of progression or
death (Table 4). In the multivariate model using these
two parameters that showed individual prognostic value,
significant interaction was noted between the number of
metastatic sites and the ECOG performance status. The
final model, incorporating the interaction terms, revealed
Table 1 Patient characteristics
Total (n = 94) CC (n = 46) CP (n = 48)
Age, years
Median (range) 63 (34–82) 62 (46–76) 63 (34–82)
Gender
Male 92 45 47
Female 2 1 1
Smoking history
Never 7 5 2
Current or former 85 39 46
Prior therapy
Surgery 31 15 16





Initial advanced state 59 29 30
Recurred state 35 17 18
Locoregional disease 4 3 1
Distant metastasis 90 43 47
No. of metastatic sites
One 45 24 21
Two or more 49 22 27
Metastatic sites
Neck, supraclavicular LN 51 24 27
Abdominal LN 42 23 19
Lung 30 10 20
Bone 17 8 9
Liver 12 6 6
CC capecitabine plus cisplatin, CP, capecitabine plus paclitaxel, ECOG, Eastern
Cooperative Oncology Group, LN, lymph nodes
Table 2 Safety of the study regimens
CC CP
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
Anemia 30 6 38 5
Neutropenia 16 16 9 18
Thrombocytopenia 24 2 7 1
Fatigue 14 0 11 1
Myalgia 0 0 23 1
Anorexia 26 0 29 2
Nausea 21 1 18 1
Vomiting 8 1 4 0
Stomatitis 11 0 20 2
Diarrhea 8 1 11 1
Constipation 6 0 5 0
Neuropathy 13 0 26 0
Alopecia 1 0 10 0
Skin 15 0 16 1
Nail changes 6 0 8 0
Table 3 Treatment response
Total (n = 94) CC (n = 46) CP (n = 48)
Best response
Complete response 2 (2 %) 0 (0 %) 2 (4 %)
Partial response 52 (55 %) 26 (57 %) 26 (54 %)
Stable disease 22 (23 %) 10 (22 %) 12 (25 %)
Progressive disease 7 (7 %) 3 (7 %) 4 (8 %)
Not evaluable 11 (12 %) 7 (15 %) 4 (8 %)
Overall response rate 54 (57 %) 26 (57 %) 28 (58 %)
Disease control rate 76 (81 %) 36 (78 %) 40 (83 %)
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that only ECOG performance status of 1 or higher
remained significant (hazard ratio 2.075, 95 % CI 1.025–
4.202, P = 0.043). There was no evidence of any significant
heterogeneity in treatment effect according to the baseline
characteristics (data not shown).
Quality of life
Baseline QOL questionnaires were completed by 93
(99 %) patients. The scores for the baseline QOL were
similar in both arms. The compliance of subsequent
QOL questionnaires decreased to 40 % at the end of
treatment. Over the whole study treatment period, there
was no relevant difference between the study arms in
the proportion of patients reporting QOL changes from
baseline to post-treatment. Symptom scales also were
similar between arms, except that reflux improved after
CC chemotherapy and dry mouth was aggravated after
CP treatment.
Discussion and conclusions
In this phase II randomized study evaluating combin-
ation chemotherapy with capecitabine plus either cis-
platin (CC) or weekly paclitaxel (CP) in patients with
metastatic squamous cell carcinoma of the esophagus,
the response rates were comparable in each arm (57 %
for CC versus 58 % for CP), demonstrating that the two
regimens were similar in terms of efficacy. This was also
the case for median PFS and OS (5.1 months and
10.5 months, respectively, for the CC arm versus
6.7 months and 13.2 months, respectively, for the CP
arm). Although the comparison between arms was per-
formed for exploratory purposes, these observations
Fig. 2 Progression-free survival for the capecitabine plus paclitaxel arm (CP, solid line) and capecitabine plus cisplatin arm (CC, dotted line)
Fig. 3 Overall survival for the capecitabine plus paclitaxel arm (CP, solid line) and capecitabine plus cisplatin arm (CC, dotted line)
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suggest that platinum-free combination chemotherapy
incorporating paclitaxel has an activity similar to that of
platinum-based chemotherapy in terms of PFS and OS.
Treatment was well tolerated with manageable toxicity
profiles. The incidence and severity of toxicity was com-
parable to that previously reported [7, 14]. Although the
compliance of patients in the QOL analysis was gener-
ally poor for both arms (40 % at the end of treatment),
QOL showed similar results between the arms. The low
compliance rate makes interpretation of the results diffi-
cult and raises the risk of bias as a result of patients with
more severe illness being less able to complete QOL
questionnaires or staff being less willing to approach
them.
The best choice of chemotherapy regimen for patients
with metastatic esophageal squamous cell carcinoma re-
mains a matter of controversy and requires further in-
vestigation. The overall response rate of 57 % and
median PFS of 5.1 months obtained with the CC arm
are consistent with those reported in our previous phase
II study that applied the same regimen [7]. The rationale
for designing the present phase II trial to compare CC
with CP was the potential for improved antitumor activity
and tolerability. 5-FU has been considered a fundamental
agent in the treatment of gastrointestinal cancers, and
several studies have shown that 5-FU can be safely re-
placed by capecitabine without reducing the efficacy
[15, 16]. A milestone phase III study of 316 patients
with gastric cancer demonstrated that the capecitabine
arm was not inferior to the 5-FU arm in terms of PFS
(5.6 months versus 5.0 months) and OS (10.5 months
versus 9.3 months) [17]. Based on studies performed
with patients with gastric or esophageal adenocarcin-
oma, capecitabine is often used in combination with cis-
platin [18]. However, it is well known that cisplatin is
associated with significant toxicity and usually requires
a high level of clinical monitoring and supportive care.
There are several ways to circumvent cisplatin-related
safety issues, including omitting the cisplatin or re-
placing it with a cytotoxic drug with similar activity.
Among others, oxaliplatin has been actively investigated
as a means to improve the efficacy and tolerability of
capecitabine-based chemotherapy [19, 20]. The use of
taxanes in combination with capecitabine merits atten-
tion. Lorenzen et al. [21] reported that patients achieved
an overall response rate of 46 % with capecitabine plus
docetaxel first-line chemotherapy. Yun et al. [14] also
reported a high response rate of 75 % with a combin-
ation of capecitabine plus paclitaxel in this setting. Con-
sidering these findings, it was anticipated that a further
Table 4 Results of Cox model for progression-free and overall survival
Progression-free survival Overall survival
HR 95 % CI P HR 95 % CI P
Age ≤60 years 1
>60 years 1.484 0.969-2.272 0.070 1.236 0.770-1.984 0.379
Smoking Never
Ever 1.080 0.496-2.353 0.846 1.076 0.465-2.494 0.864
Performance status ECOG 0
ECOG 1-2 1.110 0.661-1.862 0.694 2.381 1.215-4.673 0.012
Prior surgery No
Yes 0.799 0.512-1.246 0.322 0.608 0.361-1.024 0.061
Prior radiotherapy No
Yes 0.924 0.555-1.541 0.763 0.741 0.398-1.379 0.345
Prior chemotherapy No
Yes 0.839 0.440-1.602 0.595 1.111 0.577-2.410 0.752
No. of metastases One
≥Two 1.181 0.777-1.795 0.436 1.698 1.059-2.717 0.028
Lung metastasis No
Yes 1.119 0.624-1.764 0.858 1.201 0.701-2.012 0.488
Liver metastasis No
Yes 1.235 0.650-2.347 0.520 1.397 0.497-1.838 0.544
Treatment CC 0.219
CP 0.786 0.515-1.198 0.263 0.745 0.465-1.192
CC capecitabine plus cisplatin, CP capecitabine plus paclitaxel
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improvement in efficacy and tolerability might be
achieved by the substitution of cisplatin with weekly
paclitaxel. In the present study, an identical dose regi-
men of capecitabine was used for both arms. Thus, the
administration of cisplatin or paclitaxel was the only
variable between the two treatment arms.
The results of the present phase II study should be
interpreted with caution. We do not intend for these
data to be interpreted as stating that one regimen is bet-
ter than another. It should be kept in mind that only a
small group of patients with metastatic squamous cell
esophageal carcinoma was represented in this study, and
the study was not adequately powered to compare the
two treatment arms. Although the toxicity profiles were
generally predictable and manageable, three deaths oc-
curred that were possibly related to treatment. Of note,
one patient died of respiratory failure while his meta-
static lung disease remained stable. Pulmonary toxicity
has been reported with taxane-based chemotherapy [22],
and can sometimes be severe and even fatal. In the
current study, interstitial pneumonitis developed in two
patients in the CP arm although fortunately it was suc-
cessfully treated with corticosteroid therapy. Considering
the risk of such toxicities, our overall interpretation of
these results is that the combination of CP does not war-
rant further studies in light of the non-hematologic tox-
icities. Given the comparable efficacy results, CC might
be a reasonable first-line chemotherapy regimen for pa-
tients with metastatic esophageal squamous cell cancer.
Other active and tolerable agents are becoming available
and it is conceivable that the addition of molecularly-
targeted agents to CC chemotherapy could improve the
efficacy for treating esophageal squamous cell cancer
without compromising tolerability.
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